{"nctId":"NCT04969224","briefTitle":"A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)","startDateStruct":{"date":"2021-10-12","type":"ACTUAL"},"conditions":["Cystic Fibrosis"],"count":82,"armGroups":[{"label":"ELX/TEZ/IVA","type":"EXPERIMENTAL","interventionNames":["Drug: ELX/TEZ/IVA","Drug: IVA"]}],"interventions":[{"name":"ELX/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"name":"IVA","otherNames":["VX-770","ivacaftor"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Forced expiratory volume in 1 second (FEV1) value ≥30% and ≤90% predicted\n* Heterozygous for CF transmembrane conductance regulator gene (CFTR) F508del mutation and a minimal function mutation (F/MF genotypes)\n\nKey Exclusion Criteria:\n\n* Clinically significant liver cirrhosis\n* Solid organ or hematological transplantation\n* Non-ambulatory status\n* Lung infection with organisms associated with a more rapid decline in pulmonary status\n\nOther protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Reduction From Baseline in Cough Frequency (Cough Events Per Day) to the Average of Week 8 Through Week 12","description":"Percent reduction in cough frequency was analyzed with a mixed effects model for repeated measures (MMRM), with change from baseline at each post-baseline visit on the natural log scale as the dependent variable. The percent reduction was estimated as 100% × (1-exponential form of LS mean change estimate from the MMRM).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Total Step Count Per Day to the Average of Week 8 Through Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"637.56","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":81},"commonTop":["Headache","COVID-19","Nasopharyngitis","Diarrhoea","Abdominal pain"]}}}